Table 2

Multivariable analysis of drug discontinuation

HR95% CIP values
TCZ-IV
TCZ-SC0.930.80 to 1.090.37
Age, years1.001.00 to 1.000.85
Female gender0.960.84 to 1.090.54
Disease duration, years1.001.00 to 1.010.32
Seropositivity0.890.77 to 1.030.12
BMI1.011.00 to 1.020.22
Ever smoking1.110.97 to 1.280.14
Glucocorticoids1.161.03 to 1.310.02
Concomitant csDMARD (base=none)0.880.78 to 0.980.03
 Any csDMARD MTX0.870.76 to 1.000.04
 MTX+other csDMARDs0.790.66 to 0.940.008
 Other than MTX0.970.84 to 1.120.67
Previous bDMARDs (base=none)
 11.060.94 to 1.200.37
 21.100.94 to 1.290.25
 ≥31.100.88 to 1.380.39
CDAI at baseline1.011.00 to 1.020.001
HAQ at baseline1.141.04 to 1.260.008
ESR1.001.00 to 1.000.53
Comorbidities0.990.87 to 1.130.87
  • bDMARD, biological disease-modifying antirheumatic drug; BMI, Body Mass Index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; TCZ-IV, intravenous tocilizumab; TCZ-SC, subcutaneous tocilizumab.